Pre-ICH warfarin use, not antiplatelets, increased case fatality in spontaneous ICH patients

Y. W. Chen, S. C. Tang, L. K. Tsai, S. J. Yeh, H. Y. Chiou, P. K. Yip, J. S. Jeng

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background and purpose: Anticoagulant and antiplatelets for prevention of ischaemic stroke and cardiovascular diseases may increase the risk of intracerebral hemorrhage (ICH). This study aimed to investigate the influence of pre-ICH use of anticoagulant and antiplatelets on ICH patients. Methods: Consecutive patients with acute spontaneous ICH registered in a single-center stroke registry during 2001 to 2010 were analyzed and categorized according to their pre-ICH use of warfarin (Group I), antiplatelets (Group II), or neither (Group III). Survival analysis and the Cox proportional hazard model were used to compare between the three groups and the predictors. Results: Of 2021 ICH patients (male, 63.3%; mean age, 62.6 ± 14.4 years) included, there were 94 (4.7%) in Group I, 232 (11.4%) in Group II, and 1695 (83.9%) in Group III. Warfarin users had larger hematoma volume, more intraventricular extension, higher frequencies of lobar ICH, and higher case fatality than non-warfarin users (Groups II and III). The Cox proportional hazard model showed increased 6-month case fatality in pre-ICH warfarin users (adjusted hazard ratio 2.75, 95% confidence interval 2.04-3.72, P 

Original languageEnglish
Pages (from-to)1128-1134
Number of pages7
JournalEuropean Journal of Neurology
Volume20
Issue number8
DOIs
Publication statusPublished - Aug 2013

Keywords

  • Anticoagulants
  • Antiplatelet
  • Cerebral hemorrhage
  • Warfarin

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Fingerprint Dive into the research topics of 'Pre-ICH warfarin use, not antiplatelets, increased case fatality in spontaneous ICH patients'. Together they form a unique fingerprint.

Cite this